<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213313</url>
  </required_header>
  <id_info>
    <org_study_id>IR2019001224</org_study_id>
    <secondary_id>2019-309</secondary_id>
    <nct_id>NCT04213313</nct_id>
  </id_info>
  <brief_title>Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis</brief_title>
  <acronym>ABSOSASAPOIK</acronym>
  <official_title>Consecutive, Case Control Study of Association Between Single Nucleotide Polymorphism of SP-D and Susceptibility and Prognosis of Infectious Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores the association between single nucleotide polymorphism (Met11Thr) of
      surfactant protein D(SP-D) and susceptibility and prognosis of infectious keratitis.Met11Thr
      of SP-D of patients with keratitis and normal controls were compared.Allele and genotype
      frequencies of patients with keratitis and normal controls were determined by polymerase
      chain reaction with sequence specific primers(PCR-SSPs) .SP-D gene polymorphism of patients
      with keratitis and normal controls was detected by Sanger sequencing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surfactant protein D(SP-D) plays an important role in the innate immune system of the eye in
      the lacrimal duct, cornea and conjunctiva.The single lipopolysaccharide on the surface of
      bacteria and the receptors on the surface of immune cells are linked by SP-D ,which acts as a
      bridge to neutralize viruses in the innate immune defense system and assists other immune
      cells in clearing bacteria and fungi.SP-D can also participate in the acquired immune
      response after combining with lipopolysaccharide on the surface of microorganisms.Some single
      nucleotide polymorphisms of SP - D can not only affect the plasma level of SP - D, which
      leads to the differences of pathogen defense capability, but also can affect the space
      configuration and structure of carbohydrate recognition domain of SP-D, causing the change of
      ability of SP - D combined with pathogens to influence its defensive role.The concentration
      of SP - D in ocular surface is closely related to the occurrence and progression of
      infectious keratitis.Association between single nucleotide polymorphisms of SP-D and the
      occurrence and development of infectious keratitis has yet to be confirmed by research.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Base type</measure>
    <time_frame>before the treatment</time_frame>
    <description>Base type of SNP（rs721917）:(Met and Thr)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotype</measure>
    <time_frame>before the treatment</time_frame>
    <description>Genotype of SNP（rs721917）:( Met /Met , Thr/Thr and Met/Thr)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grading of Keratitis</measure>
    <time_frame>before the treatment</time_frame>
    <description>Grading of Keratitis：
cornea:transparency ,edema,turbidity,perforation
conjunctiva: hyperaemia
blephar:inflammation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">145</enrollment>
  <condition>Infectious Keratitis</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>health volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious Keratitis Group</arm_group_label>
    <description>Infectious corneal patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of bacterial keratitis</intervention_name>
    <description>0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID</description>
    <arm_group_label>Infectious Keratitis Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of fungal keratitis</intervention_name>
    <description>1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID</description>
    <arm_group_label>Infectious Keratitis Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of viral keratitis</intervention_name>
    <description>0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID</description>
    <arm_group_label>Infectious Keratitis Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>corneal scraping</intervention_name>
    <description>culture and sensitivity of corneal ulcerated infiltrating edge tissue</description>
    <arm_group_label>Infectious Keratitis Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sequencing</intervention_name>
    <description>polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Infectious Keratitis Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      6ml peripheral venous blood in healthy control populations and in patients with infectious
      keratitis.

      ulcerated marginal tissue in patients with infectious keratitis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with infectious keratitis at 2nd Affiliated Hospital, School of Medicine, Zhejiang
        University, China between October 2016 to June 2019
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Infectious Keratitis.

          -  Laboratory diagnosis of Infectious Keratitis.

        Exclusion Criteria:

          -  Patients with topical or systemic long-term use of hormones, interferon, or
             immunosuppressive therapy.

          -  Patients with basic diseases such as diabetes, autoimmune disease, sjogren's syndrome,
             blepharitis, eyelid defect or incomplete eyelid closure.

          -  Patients with history of corneal myopia laser, cataract surgery and vitrectomy, or
             history of serious ocular trauma and drug allergies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Jiang</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, The Second Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 24, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>January 4, 2020</last_update_submitted>
  <last_update_submitted_qc>January 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infectious Keratitis</keyword>
  <keyword>surfactant protein D</keyword>
  <keyword>single nucleotide polymorphisms</keyword>
  <keyword>Met11Thr</keyword>
  <keyword>rs721917</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

